Sonnet Biotherapeutics Holdings Inc 's

• SONN's Stock Performance relative to its Competitors

Fortress Biotech Inc Share Performance -2.67% This Quarter

Fortress Biotech Inc Profile Fortress Biotech Inc operates as a biopharmaceutical company that acquires, develops, and commercializes novel pharmaceutical and biotechnology products. Their business model focuses on partnering with academic institutions and biotech companies to advance preclinical and clinical-stage therapies for various diseases. Additionally, they aim to leverage their expertise and partnerships to improve the development process and bring innovative treatments to patients in need. More about Fortress Biotech Inc 's Market Share

Kezar Life Sciences Inc Share Performance +72.75% One Year

Kezar Life Sciences Inc Profile Kezar Life Sciences Inc is a biotechnology company that focuses on developing novel small molecule therapeutics. Their business model revolves around the discovery and development of innovative drugs to target autoimmune and inflammatory disorders, aiming to address unmet medical needs. They primarily operate by conducting extensive research and conducting clinical trials to deliver effective treatments for patients. More about Kezar Life Sciences Inc 's Market Share

Lite Strategy Inc Share Performance -36.01% This Year

Lite Strategy Inc Profile Lite Strategy, Inc. develops cancer therapies and manages a pipeline of drug candidates. More about Lite Strategy Inc 's Market Share

Lumos Pharma Inc Share Performance +34.78% This Year

Lumos Pharma Inc Profile Lumos Pharma Inc is a biopharmaceutical company that focuses on developing therapeutics for rare diseases. Their business model revolves around identifying and repurposing existing drugs to create innovative treatments for patients with unmet medical needs in the rare disease space. More about Lumos Pharma Inc 's Market Share

Madrigal Pharmaceuticals Inc Share Performance +5.48% Over The Past 5 Days

Madrigal Pharmaceuticals Inc Profile Madrigal Pharmaceuticals Inc's business model is focused on developing and commercializing innovative therapeutic solutions for liver diseases, with a particular emphasis on non-alcoholic steatohepatitis (NASH) and other metabolic diseases. They aim to provide effective treatments to address unmet medical needs and improve patient outcomes in these areas. More about Madrigal Pharmaceuticals Inc 's Market Share

Sources: Sonnet Biotherapeutics Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Monday, August 31, 2026 4:59 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Sonnet Biotherapeutics Holdings Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.